At this year’s ATiO Conference https://atioalliance.org/
PROTO’s approach includes:
- Local injection of PLX-PAD allogeneic placental cells to reduce low-grade joint inflammation.
- A customized sensor-based digital training programme designed to correct gait abnormalities and prevent further cartilage deterioration.
In a major milestone, the consortium has now initiated randomized Phase I and II clinical trials in patients with mild-to-moderate knee OA. The trials incorporate advanced biomarker profiling to stratify patient responses and monitor real-time treatment outcomes.
During the “Research vs. Reaction” segment, Prof. Winkler distilled these developments into a focused seven-minute presentation, complemented by a three-minute industry response. This dynamic exchange reflected ATiO’s mission to unite scientific breakthroughs with practical expertise, driving forward transformative orthopedic care.
